Are you over 18 and want to see adult content?
More Annotations
A complete backup of www.veinsensor.pl
Are you over 18 and want to see adult content?
A complete backup of 131458934.keywordblocks.com
Are you over 18 and want to see adult content?
A complete backup of markkavanagh.com
Are you over 18 and want to see adult content?
A complete backup of azscers.000webhostapp.com
Are you over 18 and want to see adult content?
A complete backup of abc12.onesignal.com
Are you over 18 and want to see adult content?
A complete backup of sp-active.adsrvr.org
Are you over 18 and want to see adult content?
A complete backup of services.runescape.com-api.top
Are you over 18 and want to see adult content?
A complete backup of cb1.dev.rtb.owneriq.net
Are you over 18 and want to see adult content?
Favourite Annotations
A complete backup of explicithistoire.wordpress.com
Are you over 18 and want to see adult content?
A complete backup of xalxalmektebi.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of thebellyguide.tumblr.com
Are you over 18 and want to see adult content?
A complete backup of blogdoshinhents.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of yaoihime.blogspot.com
Are you over 18 and want to see adult content?
A complete backup of czechgaysolarium.com
Are you over 18 and want to see adult content?
A complete backup of zapinterlations.com
Are you over 18 and want to see adult content?
Text
FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
THE TOP 20 PHARMA COMPANIES BY 2020 REVENUE The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTERAUTHOR: NOAHHIGGINS-DUNN
The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the1. LUCENTIS
1. Lucentis. As Roche's Lucentis faces new competition from Novartis, biosimilars are on the way. Lucentis. 2020 U.S. sales: $1.61 billion. Disease: Wet age-related macular degeneration, macular AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
NOVO NORDISK'S HIGH-DOSE OZEMPIC STALLS AT FDA'S DOOR ONAUTHOR: ANGUSLIU
Novo Nordisk’s been eyeing a weekly dosing regimen for its GLP-1 diabetes med Ozempic to better compete with Eli Lilly’s rival drug Trulicity. But that quest has hit a serious setback. The FDA MERCK PULLS BACK THE CURTAIN ON ORGANON WITH DECLININGAUTHOR: ANGUSLIU
Merck & Co. is offering a first full look at Organon, the new company it’s spinning off with its women’s health and biosimilar portfolio. And for a company aspiring to be the leading women’sFIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
THE TOP 20 PHARMA COMPANIES BY 2020 REVENUE The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTERAUTHOR: NOAHHIGGINS-DUNN
The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the1. LUCENTIS
1. Lucentis. As Roche's Lucentis faces new competition from Novartis, biosimilars are on the way. Lucentis. 2020 U.S. sales: $1.61 billion. Disease: Wet age-related macular degeneration, macular AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
NOVO NORDISK'S HIGH-DOSE OZEMPIC STALLS AT FDA'S DOOR ONAUTHOR: ANGUSLIU
Novo Nordisk’s been eyeing a weekly dosing regimen for its GLP-1 diabetes med Ozempic to better compete with Eli Lilly’s rival drug Trulicity. But that quest has hit a serious setback. The FDA MERCK PULLS BACK THE CURTAIN ON ORGANON WITH DECLININGAUTHOR: ANGUSLIU
Merck & Co. is offering a first full look at Organon, the new company it’s spinning off with its women’s health and biosimilar portfolio. And for a company aspiring to be the leading women’s JOHNSON & JOHNSON TOLD TO THROW OUT 60M COVID-19 SHOTS The FDA has instructed Johnson & Johnson to toss about 60 million COVID-19 vaccines made at Emergent BioSolutions' troubled factory in Baltimore, Maryland, the New York Times reports. THE TOP 20 PHARMA COMPANIES BY 2020 REVENUE The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other VEXED BY VECTORS: HOW COVID-19 VACCINE AND CELL AND GENE To crank out enough viral vectors to meet short-term demand for cell and gene therapies, not to mention some COVID-19 vaccines, the industry would need to have 3 billion to 6 billion liters of 2021 FORECAST: 'WE WILL NOT RETURN TO THE OLD WAYS OF As COVID-19 vaccines are rolling out in different parts of the world, perhaps it’s finally time to talk about life after the pandemic. But biopharma companies believe it’s too early to put a FIERCE PHARMA ASIA—BIOGEN, EISAI'S ALZHEIMER'S NOD Biogen's Eisai-partnered aducanumab scored its controversial FDA nod for Alzheimer's disease. China’s Stemirna Therapeutics raised $188million to
INCYTE HITS 2ND FDA DELAY IN SPAN OF DAYS, THIS TIME FOR Despite back-to-back phase 3 trial wins in atopic dermatitis, Incyte’s ruxolitinib cream isn’t immune to class-wide JAK inhibitor safety scrutiny. Just days after the FDA delayed a decisionon
BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDA Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports. PFIZER'S 'PREVNAR 20' GETS IN FDA FAST LANE AS NEXT-GEN Pfizer and Merck are both laboring away on COVID-19 vaccines, but neither has lost sight of their multibillion-dollar race for next-gen pneumococcal shots. And now, Pfizer has scored a regulatory EHA: JOHNSON & JOHNSON, NEARING SANOFI SHOWDOWN, BOLSTERS Johnson & Johnson’s Darzalex has comfortably been the only CD38 multiple myeloma drug on the market for years until Sanofi hit thescene last year
EX-SALES MANAGER-TURNED-WHISTLEBLOWER TAKES ASTRAZENECA TO A former sales manager is taking AstraZeneca to court, claiming the company discrimination against her because of her age—and because she refused to promote drugs for uses that weren't FDA-approved.FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
THE TOP 20 PHARMA COMPANIES BY 2020 REVENUE The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other ROLL CALL: HOW BIG PHARMA IS CHARTING A PATH BACK TO THE In-person pioneers. Eli Lilly has drafted a phased game plan to bring 25% of its workforce back to its downtown Indianapolis offices on June 1. Masks and social distancing will be PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports. A QUEEN OF MENOPAUSE STARS IN A LAVISH NEW SPOT FOR VAGINA TherapeuticsMD’s new ad for Imvexxy is all about female fun and empowerment—including after menopause. The video ad evokes a lavish “Bridgerton” period drama feel, featuring a glamorous EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
THE TOP 20 PHARMA COMPANIES BY 2020 REVENUE The pharma industry quickly took center stage when COVID-19 caught the world off guard early last year. As 2020 progressed, drugmakers battled the coronavirus on one hand and on the other ROLL CALL: HOW BIG PHARMA IS CHARTING A PATH BACK TO THE In-person pioneers. Eli Lilly has drafted a phased game plan to bring 25% of its workforce back to its downtown Indianapolis offices on June 1. Masks and social distancing will be PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports. A QUEEN OF MENOPAUSE STARS IN A LAVISH NEW SPOT FOR VAGINA TherapeuticsMD’s new ad for Imvexxy is all about female fun and empowerment—including after menopause. The video ad evokes a lavish “Bridgerton” period drama feel, featuring a glamorous EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
VEXED BY VECTORS: HOW COVID-19 VACCINE AND CELL AND GENE To crank out enough viral vectors to meet short-term demand for cell and gene therapies, not to mention some COVID-19 vaccines, the industry would need to have 3 billion to 6 billion liters of JOHNSON & JOHNSON'S COVID-19 VACCINE SCORES LONGER SHELF Just as millions of Johnson & Johnson COVID-19 vaccines were set to expire by June's end, the FDA on Thursday said the jabs could be kept on the shelf a month and half longer than originally THE 10 MOST-ANTICIPATED DRUG LAUNCHES OF 2021 Leading the way is the industry’s love-hate Alzheimer’s candidate aducanumab from Biogen and Eisai. The backstory of the drug alone could fill all 10 pages of this special report, but suffice THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 TEVA, AFTER LOCKING UP NEW AJOVY PATENTS, SUES ELI LILLY The CGRP patent fight between Ajovy maker Teva Pharmaceuticals and Emgality developer Eli Lilly is only heating up. Teva filed a new suitagainst Lilly in
CHANGE TO GILEAD ASSISTANCE PROGRAM THREATENS PREP ACCESS Nationwide, safety-net clinics rely on Gilead’s Advancing Access Patient Assistance/Medication Assistance Program to fund services that keep patients in need HIV-negative. But a change to how BIOGEN'S HEFTY ADUHELM COST SPARKS EVEN MORE TALK OF A Just as analysts warned, drug price reform advocates in Washington, D.C. have been quick to blast Biogen for placing a $56,000 annualprice tag on
BRISTOL MYERS' CELL THERAPY BREYANZI, FRESH OFF AN FDA NOD Existing CD19-directed CAR-T therapies are all reserved for certain large B-cell lymphoma patients who’ve tried at least two prior therapies. But Bristol Myers Squibb, the latest player to join ABBVIE'S BOTOX ROLLS OUT THE RED CARPET FOR REAL PEOPLE IN AbbVie's new campaign for Botox is a sea change in its marketing, moving from glamorous young women to everyday real people who use theproduct.
FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
ROLL CALL: HOW BIG PHARMA IS CHARTING A PATH BACK TO THE In-person pioneers. Eli Lilly has drafted a phased game plan to bring 25% of its workforce back to its downtown Indianapolis offices on June 1. Masks and social distancing will be THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 AS ORGANON CHARTS POST-SPINOFF FUTURE, MERCK'S $9B CASH Merck's Monday investor call centered on Organon's plan to make a splash in the women's health sector, but the spinoff may put Merck in a prime position to strike an M&A deal. JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports. A QUEEN OF MENOPAUSE STARS IN A LAVISH NEW SPOT FOR VAGINA TherapeuticsMD’s new ad for Imvexxy is all about female fun and empowerment—including after menopause. The video ad evokes a lavish “Bridgerton” period drama feel, featuring a glamorous EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
ROLL CALL: HOW BIG PHARMA IS CHARTING A PATH BACK TO THE In-person pioneers. Eli Lilly has drafted a phased game plan to bring 25% of its workforce back to its downtown Indianapolis offices on June 1. Masks and social distancing will be THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 AS ORGANON CHARTS POST-SPINOFF FUTURE, MERCK'S $9B CASH Merck's Monday investor call centered on Organon's plan to make a splash in the women's health sector, but the spinoff may put Merck in a prime position to strike an M&A deal. JOHNSON & JOHNSON SNARES FDA NOD FOR FIRST EXON 20 Now christened Rybrevant, the drug is the first-ever treatment for non-small cell lung cancer with a group of epidermal growth factor receptor (EGFR) mutations found in 2% to 3% of patients, the AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for a BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports. A QUEEN OF MENOPAUSE STARS IN A LAVISH NEW SPOT FOR VAGINA TherapeuticsMD’s new ad for Imvexxy is all about female fun and empowerment—including after menopause. The video ad evokes a lavish “Bridgerton” period drama feel, featuring a glamorous EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
VEXED BY VECTORS: HOW COVID-19 VACCINE AND CELL AND GENE To crank out enough viral vectors to meet short-term demand for cell and gene therapies, not to mention some COVID-19 vaccines, the industry would need to have 3 billion to 6 billion liters of JOHNSON & JOHNSON'S COVID-19 VACCINE SCORES LONGER SHELF Just as millions of Johnson & Johnson COVID-19 vaccines were set to expire by June's end, the FDA on Thursday said the jabs could be kept on the shelf a month and half longer than originally THE 10 MOST-ANTICIPATED DRUG LAUNCHES OF 2021 Leading the way is the industry’s love-hate Alzheimer’s candidate aducanumab from Biogen and Eisai. The backstory of the drug alone could fill all 10 pages of this special report, but suffice THE TOP 20 DRUGS BY WORLDWIDE SALES IN 2020 The drug generated $7.12 billion in 2019, enough for the No. 8 spot, but as biosim challengers gained steam, sales fell to $5.32 billion in2020.
PFIZER, ASTRAZENECA COVID VACCINES PROBED IN EUROPE AFTER The European Medicines Agency’s safety committee said on Friday that it's evaluating an assortment of potential side effects following inoculation with most leading COVID-19 TEVA, AFTER LOCKING UP NEW AJOVY PATENTS, SUES ELI LILLY The CGRP patent fight between Ajovy maker Teva Pharmaceuticals and Emgality developer Eli Lilly is only heating up. Teva filed a new suitagainst Lilly in
CHANGE TO GILEAD ASSISTANCE PROGRAM THREATENS PREP ACCESS Nationwide, safety-net clinics rely on Gilead’s Advancing Access Patient Assistance/Medication Assistance Program to fund services that keep patients in need HIV-negative. But a change to how BIOGEN'S HEFTY ADUHELM COST SPARKS EVEN MORE TALK OF A Just as analysts warned, drug price reform advocates in Washington, D.C. have been quick to blast Biogen for placing a $56,000 annualprice tag on
BRISTOL MYERS' CELL THERAPY BREYANZI, FRESH OFF AN FDA NOD Existing CD19-directed CAR-T therapies are all reserved for certain large B-cell lymphoma patients who’ve tried at least two prior therapies. But Bristol Myers Squibb, the latest player to join ABBVIE'S BOTOX ROLLS OUT THE RED CARPET FOR REAL PEOPLE IN AbbVie's new campaign for Botox is a sea change in its marketing, moving from glamorous young women to everyday real people who use theproduct.
FIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports.1. LUCENTIS
1. Lucentis. As Roche's Lucentis faces new competition from Novartis, biosimilars are on the way. Lucentis. 2020 U.S. sales: $1.61 billion. Disease: Wet age-related macular degeneration, macular AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for aFRAISER KANSTEINER
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
ABBVIE REVIVES ALLERGAN'S ABANDONED WOMEN'S HEALTH SALEAUTHOR: ANGUSLIU
In 2020, AbbVie’s women’s health revenue dropped 13.3% on an operational basis to $673 million. In 2019, Allergan’s women’s health franchise raked in $896 million after 13.8% year-over FDA KNOCKS ACELLA FOR LAX CONTROLS ON THYROID MEDICINE FDA knocks Acella for lax controls on thyroid medicine recalled in May. The FDA found that Acella failed to create adequate assays for its thyroid med NP Thyroid. (FDA) As the pharmaceutical NOVARTIS, WORKING TO IMPROVE ALCON, GIVES BACK Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea. At one time, analysts had projected Jetrea could hit about $500 million in annual sales, but in GLAXOSMITHKLINE'S BENLYSTA EYES LUPUS SALES BOOST AFTERBENLYSTA ADMINISTRATIONBENLYSTA BELIMUMABBENLYSTA BELIMUMABBENLYSTA GATEWAYBENLYSTA IMMUNOSUPPRESSION GlaxoSmithKline's Benlysta has long enjoyed its place as the sole biologic approved to treat lupus, despite other drugmakers' forays into the field. But with competitors sniffing around, GSK isFIERCEPHARMA
Visit FiercePharma for pharma industry news on big pharma, FDA decisions, patents, pharmaceutical marketing, generic drugs, and otherpharma news.
BIDEN EXPANDS HIS LIST OF POTENTIAL NOMINEES TO LEAD FDAAUTHOR: NOAHHIGGINS-DUNN
Despite urgent pleas for the Biden administration to choose a permanent FDA commissioner, the list of potential nominees has grown even larger, The Wall Street Journal reports.1. LUCENTIS
1. Lucentis. As Roche's Lucentis faces new competition from Novartis, biosimilars are on the way. Lucentis. 2020 U.S. sales: $1.61 billion. Disease: Wet age-related macular degeneration, macular AHEAD OF POTENTIAL SEMAGLUTIDE APPROVAL IN CHRONIC OBESITY Novo Nordisk has started the year on solid footing, thanks in no small part to its GLP-1 portfolio in Type 2 diabetes. With top earner semaglutide (approved in diabetes as Ozempic) due for aFRAISER KANSTEINER
Fraiser Kansteiner is a staff writer at Fierce Pharma. He joined the Fierce team in 2020 and covers topics such as manufacturing, COVID-19 and drug delivery. He also manages Fierce Biotech and EOHILIA MAKER TAKEDA TARGETS DOCTORS IN A FIRST-TIME Takeda's newest campaign to physicians launches as it awaits an FDA decision for its eosinophilic esophagitis treatment Eohilia—andjumps ahead of
ABBVIE REVIVES ALLERGAN'S ABANDONED WOMEN'S HEALTH SALEAUTHOR: ANGUSLIU
In 2020, AbbVie’s women’s health revenue dropped 13.3% on an operational basis to $673 million. In 2019, Allergan’s women’s health franchise raked in $896 million after 13.8% year-over FDA KNOCKS ACELLA FOR LAX CONTROLS ON THYROID MEDICINE FDA knocks Acella for lax controls on thyroid medicine recalled in May. The FDA found that Acella failed to create adequate assays for its thyroid med NP Thyroid. (FDA) As the pharmaceutical NOVARTIS, WORKING TO IMPROVE ALCON, GIVES BACK Novartis, working to improve Alcon, gives back ThromboGenics drug Jetrea. At one time, analysts had projected Jetrea could hit about $500 million in annual sales, but in GLAXOSMITHKLINE'S BENLYSTA EYES LUPUS SALES BOOST AFTERBENLYSTA ADMINISTRATIONBENLYSTA BELIMUMABBENLYSTA BELIMUMABBENLYSTA GATEWAYBENLYSTA IMMUNOSUPPRESSION GlaxoSmithKline's Benlysta has long enjoyed its place as the sole biologic approved to treat lupus, despite other drugmakers' forays into the field. But with competitors sniffing around, GSK is MERCK INVESTIGATING NOOSE AT NC VACCINE PLANT AS EXECS A noose was found hanging over a beam at a construction site at a Merck manufacturing facility in Durham, N.C. The New Jersey-based company sent an email to employees on Saturday, informing them MARKETING | FIERCEPHARMA Merck details Keytruda's Herceptin combo stomach cancer win. The FDA granted Keytruda a quick go-ahead based on the interim tumor responseanalysis,
BIOGEN'S ADUCANUMAB CROSSES FDA FINISH LINE JUST IN TIME The verdict is in: The FDA has approved Biogen’s controversial Alzheimer’s treatment aducanumab. The FDA’s approval on Monday isset to cause
NOVEOME POSTS CLINICAL DATA ON NOSE-TO-BRAIN DELIVERY Noveome Biotherapeutics has presented phase 1 data on its nasally delivered glaucoma candidate ST266. The safety and tolerability datatee Noveome
BLUEBIRD'S ZYNTEGLO TRIALS SET TO RESUME, PUTTING GENE Bluebird Bio's beta-thalassemia gene therapy Zynteglo has struggled to spread its wings, and a recent clinical pause certainly didn't help. But with studies on several bluebird drugs set to BIOGEN'S 'SHOCKINGLY BROAD' ADUHELM LABEL—AND $56K PRICE Biogen didn't just win the most closely watched FDA green light of the year. It snagged a "shockingly broad" label, set an aggressive $56,000 price and now stands poised for "one of the biggest ASCO: ASTRAZENECA DETAILS CALQUENCE'S HEART SAFETY EDGE 23 hours ago · Without an efficacy edge, AstraZeneca is aiming to lure doctors away from AbbVie and Johnson & Johnson’s market-leading Imbruvica by touting a better safety profile for its rival BTKinhibitor
BIOGEN'S HIGH PRICE FOR ADUHELM—PLUS THE DRUG'S BROAD The hefty price tag, sweeping label and potential popularity of Biogen's newly approved Alzheimer's disease drug Aduhelm could createa heavy burden on
ROLL CALL: HOW BIG PHARMA IS CHARTING A PATH BACK TO THE In-person pioneers. Eli Lilly has drafted a phased game plan to bring 25% of its workforce back to its downtown Indianapolis offices on June 1. Masks and social distancing will be READY, SET, PRESCRIBE? DOCTORS DETAIL WHY THEY'LL DEPLOY At the Washington University School of Medicine in St. Louis, the phone lines were “blowing up” Monday. Alzheimer's patients and family members were calling about Biogen and Eisai's Aduhelm Skip to main contentMAIN NAVIGATION
* Manufacturing
* Marketing
* Pharma
* Vaccines
* Special Topics
* Drug Delivery
* COVID-19
* Consumer Health
* Supply Chain
MAIN NAVIGATION - MOBILE* Manufacturing
* Marketing
* Pharma
* Vaccines
* Special Topics
* Drug Delivery
* COVID-19
* Consumer Health
* Supply Chain
TOP MENU
* Virtual Events
* FierceBiotech
* Jobs
* Resources
* Webinars
* Industry Events
* Subscribe
* Special Reports
Twitter LinkedIn
Search
Enclose phrases in quotes. Use a + to require a term in results and -to exclude terms.
Example: +water -EuropeTOP MENU
* Virtual Events
* FierceBiotech
* Jobs
* Resources
* Webinars
* Industry Events
* Subscribe
* Special Reports
Twitter LinkedIn
Marketing
PNEUMONIA AWARENESS EFFORT ILLUMINATES ICONIC STRUCTURES by Sharon Klahr CoeyNov 20, 2020,
12:53 PM
Pharma
COVID-19 TRACKER: NOVARTIS, MESOBLAST, CUE, SII, AZ AND MOREby Eric Sagonowsky,
Angus Liu,
Kyle Blankenship,
Conor Hale,
Fraiser Kansteiner
Nov 20,
2020, 12:15 PM
Drug Delivery
RESEARCHERS SPOTLIGHT A SAFER METHOD FOR CRISPR DELIVERY by Fraiser KansteinerNov 20,
2020, 9:03 AM
Marketing
PHARMA BRANDS SHOULD SKIP CELEBS FOR SOCIAL INFLUENCER ADS by Beth Snyder BulikNov 20, 2020,
8:51 AM
Pharma
LILLY SCORES EMERGENCY AUTHORIZATION FOR OLUMIANT IN COVID-19by Eric Sagonowsky
Nov 20, 2020,
8:44 AM
Marketing
NOVO NORDISK DEBUTS CHINESE-LANGUAGE CHATBOT FOR DIABETES INFO More than one-fourth of the world's diabetes patients live in China—and Novo Nordisk wants to give them a better way to ask questions and get info. by Sharon Klahr CoeyNov 20, 2020,
11:31 AM
Pharma
WHO RECOMMENDS AGAINST GILEAD'S REMDESIVIR IN COVID-19 Experts at the WHO said they found no evidence that remdesivir has any meaningful effect on saving lives and other important outcomes forpatients.
by Angus Liu Nov 20,2020, 11:22 AM
Sponsored
STAYING IN-TUNE WITH PHARMA CONSUMERS - EMBRACING DIGITAL AUDIO 3 in every 4 Americans have changed routines in 2020, digital audio and video streaming continues to be front and center with consumers. sponsored by Pandora Nov16, 2020, 8:00 AM
Pharma
TRUMP TO UNVEIL NEW DRUG PRICING RULES: REPORTS President Donald Trump appears poised to unveil new drug pricing rules that could shake up U.S. pricing dynamics in a big way.by Eric Sagonowsky
Nov 20, 2020,
10:55 AM
Pharma Asia
SAMSUNG BIOLOGICS, ELI LILLY AND ASTRAZENECA—FIERCEPHARMAASIA Samsung Biologics makes Lilly's COVID antibody drug, just as it disbands an AstraZeneca joint venture. AZ's ex-China R&D head launchesnew firm.
by Angus Liu Nov 20,2020, 10:50 AM
Sponsored
EMBODYING EMPATHY: A PATH TO DEEPER AUDIENCE CONNECTIONS See how health brands can harness the power of empathy to fuel deeper connections with and better serve their audiences. sponsored by Verywell Nov 9, 2020, 8:00 AMDrug Delivery
APIJECT BAGS $590M TO MAKE INJECTOR DEVICES FOR COVID VACCINES ApiJect systems snared a $590 million from the U.S. government to build a multi-facility campus to crank out more than 3 billioninjectors per year.
by Fraiser KansteinerNov 20, 2020,
9:43 AM
Manufacturing
FRESENIUS PULLS HOSPITAL SEDATIVE AGAIN FOR LIDOCAINE MIXUP Fresenius Kabi has recalled one lot of a surgical sedative because of cross-contamination with lidocaine, which could cause severe allergicreactions.
by Kyle Blankenship
Nov 20, 2020,
8:15 AM
Pharma
NEW HOUSE BILL SEEKS TO CLOSE ORPHAN DRUG EXCLUSIVITY LOOPHOLE A new House bill has passed that would require orphan drug market exclusivity seekers to prove that they don't expect to recoup R&Dcosts.
by Angus Liu Nov 19,2020, 12:11 PM
Marketing
HHS CANCELS CELEBRITIES, KEEPS SCIENCE IN BIG PANDEMIC AD EFFORT HHS' proposed $250 million pandemic campaign will continue, although without celebrity messaging, and refocus on science. by Beth Snyder BulikNov 19, 2020,
11:49 AM
* Previous
* 1
* View More
GET THE NEWSLETTER
Subscribe to FiercePharma to get industry news and updates deliveredto your inbox.
I acknowledge that I may receive emails from FiercePharma and on behalf of their trusted partners.* GENERAL
* Home
* Privacy
* Terms of Use
* RSS
* CONTACT
* Advertise
* About Us
* NEWSLETTERS
* Subscribe
* Manage Subscriptions* Connect
*
*
2020 Questex LLC. All rights reserved. 3 Speen Street, Suite 300, Framingham, MA 01701 Reproduction in whole or part is prohibited._FREE WEBINAR _
FROM PATIENT ADHERENCE TO MANUFACTURING EASE: WHY SOFTGELS MAKE SENSEFOR RX
Wednesday, December 211am ET / 8am PT
Learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easyscale-up.
Save Your Spot
x
Details
Copyright © 2024 ArchiveBay.com. All rights reserved. Terms of Use | Privacy Policy | DMCA | 2021 | Feedback | Advertising | RSS 2.0